Explorations of the S 1 0 subsite of ACE2 via modifications of the P 1 0 methylene biphenyl moiety of thiol-based metalloprotease inhibitors led to improvements in ACE2 selectivity versus ACE and NEP, while maintaining potent ACE2 inhibition. 